↓ Skip to main content
Embed badge What is this page?

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
48 Mendeley

What is this page?

Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
Published in
Journal for Immunotherapy of Cancer, October 2014
DOI 10.1186/s40425-014-0034-0
Pubmed ID
25328681
Authors

Stefanie J Mandl, Ryan B Rountree, Tracy B dela Cruz, Susan P Foy, Joseph J Cote, Evan J Gordon, Erica Trent, Alain Delcayre, Alex Franzusoff

Abstract

PROSTVAC®, an active immunotherapy currently studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC), consists of a heterologous prime-boost regimen with two different poxvirus-based vectors to provoke productive immune responses against prostate specific antigen (PSA) as the target tumor antigen. A Phase 2 study of PROSTVAC immunotherapy showed significantly improved median overall survival by 8.5 months and is currently being validated in a global Phase 3 study (PROSPECT; NCT01322490). Here, preclinical models were explored to investigate the mechanism of action and immune signatures of anti-tumor efficacy with PROSTVAC immunotherapy with the goal to identify potential immune correlates of clinical benefit.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
France 1 2%
Unknown 46 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 27%
Student > Master 8 17%
Student > Bachelor 6 13%
Student > Ph. D. Student 4 8%
Professor 2 4%
Other 7 15%
Unknown 8 17%
Readers by discipline Count As %
Medicine and Dentistry 15 31%
Agricultural and Biological Sciences 8 17%
Immunology and Microbiology 8 17%
Biochemistry, Genetics and Molecular Biology 4 8%
Earth and Planetary Sciences 1 2%
Other 3 6%
Unknown 9 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2014.
All research outputs
#4,198,909
of 5,036,385 outputs
Outputs from Journal for Immunotherapy of Cancer
#182
of 194 outputs
Outputs of similar age
#114,815
of 143,251 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#27
of 28 outputs
Altmetric has tracked 5,036,385 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 194 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,251 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.